ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- The Benefit of Short-Term Androgen Deprivation Therapy with Radiation Therapy for Intermediate-Risk Prostate Cancer.International journal of radiation oncology, biology, physics · 2025Pooled it
- Genomic classifiers and prognosis of localized prostate cancer: a systematic review.Prostate cancer and prostatic diseases · 2025Pooled it
- Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials.Prostate cancer and prostatic diseases · 2024Pooled it
- Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.International journal of radiation oncology, biology, physics · 2023Trial
- Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Absolute Benefit of Androgen Deprivation Therapy With Radiotherapy for Localized Prostate Cancer.medRxiv : the preprint server for health sciences · 2026Article
- Overall Survival in Men 80 and Older With Intermediate-Risk Prostate Cancer Who are Treated With Dose-Escalated Radiation and Androgen Deprivation Therapy Versus Dose-Escalated Radiation Alone: A National Cancer Database Analysis.Advances in radiation oncology · 2026Article
- Predictive Value of Quantitative ADC, SUVmax, and the SUVmax/ADC Ratio for Biological Behavior and Prognosis in High-Risk Prostate Cancer.Journal of clinical medicine · 2025Article
- Pelvic lymph node management in prostate cancer: a narrative review.Prostate international · 2025Review
- Radioprotection of healthy tissue via nanoparticle-delivered mRNA encoding for a damage-suppressor protein found in tardigrades.Nature biomedical engineering · 2025Article
- Optimizing Radiation Therapy for Localized Prostate Cancer: Exploring Synergies With Androgen Deprivation Therapy and Novel Systemic Agents.Seminars in radiation oncology · 2025Review
- Radiation Promotes Acute and Chronic Damage to Adipose Tissue.International journal of molecular sciences · 2025Article
- Predicting intermediate-risk prostate cancer using machine learning.International urology and nephrology · 2025Article
- Article
- Impact of androgen deprivation therapy in patients with unfavorable intermediate-risk prostate cancer receiving brachytherapy-based dose-escalated radiation therapy.Journal of contemporary brachytherapy · 2024Article
- Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities.Clinical and translational radiation oncology · 2024Review
- Prostate-specific antigen kinetics in hypofractionated radiation therapy alone for intermediate- and high-risk localized prostate cancer.Prostate international · 2023Article
- Discordant molecular biomarkers in unfavorable intermediate-risk localized prostate cancer.CA: a cancer journal for cliniciansArticle
Corrections and comments
- Commented on by
Authors and funding
21 authors at 16 institutions in 2 countries.
Funding
Abstract
purposeIt remains unknown whether or not short-term androgen deprivation (STAD) improves survival among men with intermediate-risk prostate cancer (IRPC) treated with dose-escalated radiotherapy (RT).
methodsThe NRG Oncology/Radiation Therapy Oncology Group 0815 study randomly assigned 1,492 patients with stage T2b-T2c, Gleason score 7, or prostate-specific antigen (PSA) value >10 and ≤20 ng/mL to dose-escalated RT alone (arm 1) or with STAD (arm 2). STAD was 6 months of luteinizing hormone-releasing hormone agonist/antagonist therapy plus antiandrogen. RT modalities were external-beam RT alone to 79.2 Gy or external beam (45 Gy) with brachytherapy boost. The primary end point was overall survival (OS). Secondary end points included prostate cancer-specific mortality (PCSM), non-PCSM, distant metastases (DMs), PSA failure, and rates of salvage therapy.
resultsMedian follow-up was 6.3 years. Two hundred nineteen deaths occurred, 119 in arm 1 and 100 in arm 2. Five-year OS estimates were 90% versus 91%, respectively (hazard ratio [HR], 0.85; 95% CI, 0.65 to 1.11];
conclusionSTAD did not improve OS rates for men with IRPC treated with dose-escalated RT. Improvements in metastases rates, prostate cancer deaths, and PSA failures should be weighed against the risk of adverse events and the impact of STAD on quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.